Taysha Gene Therapies (TSHA) Beginning Cash Balance (2020)
Taysha Gene Therapies' (TSHA) quarterly Beginning Cash Balance came in at $28000.0 in Q3 2020, up 2900.0% quarter-over-quarter from -$1000.0 in Q2 2020.
Taysha Gene Therapies (TSHA) Beginning Cash Balance (2020) Analysis & Trends
Taysha Gene Therapies has disclosed Beginning Cash Balance across 1 years of filings, most recently posting $28000.0 for Q3 2020.
- Beginning Cash Balance for Q3 2020 came in at $28000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $1.7 million (changed N/A YoY), and the FY2020 annual result was $1.7 million, changed N/A from the prior year.
- Beginning Cash Balance came in at $28000.0 for Q3 2020 at Taysha Gene Therapies, up from -$1000.0 in the prior quarter.
- In the past five years, Beginning Cash Balance ranged from a high of $1.6 million in Q1 2020 to a low of -$1000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 28,000.00 |
| Sep 30, 2020 | 28,000.00 |
| Jun 30, 2020 | -1,000.00 |
| Jun 30, 2020 | -1,000.00 |
| Mar 31, 2020 | 1.65 Mn |
| Mar 31, 2020 | 1.65 Mn |